Cabaletta Bio (CABA) has issued an update.
Cabaletta Bio, Inc. has unveiled promising initial clinical data from its innovative CABA-201 therapy trials aimed at autoimmune diseases, presented at the prestigious EULAR 2024 Congress. The treatment involves a single infusion designed to deplete B cells and potentially reset the immune system, offering a chance for durable remission without the need for ongoing therapy. With positive safety and tolerability results from the first two patients, showing significant clinical improvements, Cabaletta’s RESET clinical development program is advancing, indicating a transformative step forward in autoimmune disease treatment.
See more data about CABA stock on TipRanks’ Stock Analysis page.
